instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
What was the outcome of reaction 'Latent tuberculosis'? | Management of MDA-5 antibody-positive dermatomyositis with interstitial lung disease-an Auckland case series.
The aim was to present our experience of managing six cases of anti-melanoma differentiation-associated gene 5 (anti-MDA-5) DM with associated interstitial lung disease (ILD), presenting between June 2017 and O... | Recovering | ReactionOutcome | CC BY-NC | 33898921 | 19,879,836 | 2021 |
What was the outcome of reaction 'Pulmonary cavitation'? | Management of MDA-5 antibody-positive dermatomyositis with interstitial lung disease-an Auckland case series.
The aim was to present our experience of managing six cases of anti-melanoma differentiation-associated gene 5 (anti-MDA-5) DM with associated interstitial lung disease (ILD), presenting between June 2017 and O... | Recovering | ReactionOutcome | CC BY-NC | 33898921 | 19,908,010 | 2021 |
What was the outcome of reaction 'Serum ferritin increased'? | Management of MDA-5 antibody-positive dermatomyositis with interstitial lung disease-an Auckland case series.
The aim was to present our experience of managing six cases of anti-melanoma differentiation-associated gene 5 (anti-MDA-5) DM with associated interstitial lung disease (ILD), presenting between June 2017 and O... | Recovered | ReactionOutcome | CC BY-NC | 33898921 | 19,897,239 | 2021 |
What was the outcome of reaction 'Skin ulcer'? | Management of MDA-5 antibody-positive dermatomyositis with interstitial lung disease-an Auckland case series.
The aim was to present our experience of managing six cases of anti-melanoma differentiation-associated gene 5 (anti-MDA-5) DM with associated interstitial lung disease (ILD), presenting between June 2017 and O... | Recovered | ReactionOutcome | CC BY-NC | 33898921 | 19,897,215 | 2021 |
What was the outcome of reaction 'Substance-induced psychotic disorder'? | Management of MDA-5 antibody-positive dermatomyositis with interstitial lung disease-an Auckland case series.
The aim was to present our experience of managing six cases of anti-melanoma differentiation-associated gene 5 (anti-MDA-5) DM with associated interstitial lung disease (ILD), presenting between June 2017 and O... | Recovered | ReactionOutcome | CC BY-NC | 33898921 | 19,897,217 | 2021 |
What was the outcome of reaction 'Tuberculosis'? | Management of MDA-5 antibody-positive dermatomyositis with interstitial lung disease-an Auckland case series.
The aim was to present our experience of managing six cases of anti-melanoma differentiation-associated gene 5 (anti-MDA-5) DM with associated interstitial lung disease (ILD), presenting between June 2017 and O... | Recovering | ReactionOutcome | CC BY-NC | 33898921 | 19,908,010 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Asthma'. | Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study.
BACKGROUND
Limited knowledge exists on outcomes of children exposed prenatally to chemotherapy for breast cancer (BC). The purpose of this study was to compare long-term neurocognitive, ... | CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33901920 | 20,099,713 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Caesarean section'. | Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study.
BACKGROUND
Limited knowledge exists on outcomes of children exposed prenatally to chemotherapy for breast cancer (BC). The purpose of this study was to compare long-term neurocognitive, ... | CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, FLUOROURACIL, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33901920 | 20,095,429 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Congenital anomaly'. | Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study.
BACKGROUND
Limited knowledge exists on outcomes of children exposed prenatally to chemotherapy for breast cancer (BC). The purpose of this study was to compare long-term neurocognitive, ... | CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33901920 | 20,099,713 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Death'. | Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study.
BACKGROUND
Limited knowledge exists on outcomes of children exposed prenatally to chemotherapy for breast cancer (BC). The purpose of this study was to compare long-term neurocognitive, ... | CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, FLUOROURACIL, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33901920 | 20,095,429 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dermatitis atopic'. | Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study.
BACKGROUND
Limited knowledge exists on outcomes of children exposed prenatally to chemotherapy for breast cancer (BC). The purpose of this study was to compare long-term neurocognitive, ... | CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33901920 | 20,099,713 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Eczema'. | Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study.
BACKGROUND
Limited knowledge exists on outcomes of children exposed prenatally to chemotherapy for breast cancer (BC). The purpose of this study was to compare long-term neurocognitive, ... | CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33901920 | 20,099,713 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypersensitivity'. | Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study.
BACKGROUND
Limited knowledge exists on outcomes of children exposed prenatally to chemotherapy for breast cancer (BC). The purpose of this study was to compare long-term neurocognitive, ... | CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33901920 | 20,099,713 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ill-defined disorder'. | Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study.
BACKGROUND
Limited knowledge exists on outcomes of children exposed prenatally to chemotherapy for breast cancer (BC). The purpose of this study was to compare long-term neurocognitive, ... | CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33901920 | 20,099,713 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Infection'. | Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study.
BACKGROUND
Limited knowledge exists on outcomes of children exposed prenatally to chemotherapy for breast cancer (BC). The purpose of this study was to compare long-term neurocognitive, ... | CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33901920 | 20,099,713 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Maternal exposure during pregnancy'. | Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study.
BACKGROUND
Limited knowledge exists on outcomes of children exposed prenatally to chemotherapy for breast cancer (BC). The purpose of this study was to compare long-term neurocognitive, ... | CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, FLUOROURACIL, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33901920 | 20,095,429 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oral candidiasis'. | Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study.
BACKGROUND
Limited knowledge exists on outcomes of children exposed prenatally to chemotherapy for breast cancer (BC). The purpose of this study was to compare long-term neurocognitive, ... | CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33901920 | 20,099,713 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Premature baby'. | Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study.
BACKGROUND
Limited knowledge exists on outcomes of children exposed prenatally to chemotherapy for breast cancer (BC). The purpose of this study was to compare long-term neurocognitive, ... | CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33901920 | 20,099,713 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Premature delivery'. | Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study.
BACKGROUND
Limited knowledge exists on outcomes of children exposed prenatally to chemotherapy for breast cancer (BC). The purpose of this study was to compare long-term neurocognitive, ... | CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, FLUOROURACIL, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33901920 | 20,095,429 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Social (pragmatic) communication disorder'. | Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study.
BACKGROUND
Limited knowledge exists on outcomes of children exposed prenatally to chemotherapy for breast cancer (BC). The purpose of this study was to compare long-term neurocognitive, ... | CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33901920 | 20,099,713 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Unevaluable event'. | Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study.
BACKGROUND
Limited knowledge exists on outcomes of children exposed prenatally to chemotherapy for breast cancer (BC). The purpose of this study was to compare long-term neurocognitive, ... | CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33901920 | 20,099,713 | 2021-08 |
What was the outcome of reaction 'Death'? | Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study.
BACKGROUND
Limited knowledge exists on outcomes of children exposed prenatally to chemotherapy for breast cancer (BC). The purpose of this study was to compare long-term neurocognitive, ... | Fatal | ReactionOutcome | CC BY-NC-ND | 33901920 | 20,095,429 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Appendicitis'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arthralgia'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cellulitis'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Chest pain'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cholangitis'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Clostridium difficile infection'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Colitis'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dehydration'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diverticulitis intestinal perforated'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Endocarditis'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fatigue'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Febrile neutropenia'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatic enzyme abnormal'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Herpes zoster'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Infection'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Insomnia'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Malaise'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Mucosal inflammation'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myalgia'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nephropathy toxic'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neuropathy peripheral'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutrophil count decreased'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pain'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pancreatitis'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonitis'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pulmonary embolism'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyrexia'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rash'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Root canal infection'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sinus tachycardia'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Staphylococcal infection'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Subcutaneous abscess'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombosis'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Unevaluable event'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vomiting'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'White blood cell count increased'. | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | CIPROFLOXACIN, CYCLOPHOSPHAMIDE, DOCETAXEL, FILGRASTIM, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
What was the administration route of drug 'CIPROFLOXACIN'? | A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
BACKGROUND
Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetax... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33901921 | 19,395,027 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma.
Tirabrutinib (ONO/GS-4059; Ono Pharmaceutical) is a newly developed drug that selectively and irreversibly inhibits Bruton's tyrosine kinase (BTK) and has been approved in Japan for treatin... | METHYLPREDNISOLONE, PIPERACILLIN SODIUM\TAZOBACTAM SODIUM, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY | 33902692 | 20,143,474 | 2021-04-26 |
What was the outcome of reaction 'Drug ineffective'? | Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma.
Tirabrutinib (ONO/GS-4059; Ono Pharmaceutical) is a newly developed drug that selectively and irreversibly inhibits Bruton's tyrosine kinase (BTK) and has been approved in Japan for treatin... | Fatal | ReactionOutcome | CC BY | 33902692 | 20,143,474 | 2021-04-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cataract'. | A Rare Case of Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of Unknown Primary Origin.
BACKGROUND Pembrolizumab is a humanized monoclonal antibody against programmed cell death-1 protein. Pembrolizumab sometimes causes immune-related adverse events (irAEs). Dermatomyositis is a rare irAE of immune che... | LEVOFLOXACIN, METHYLPREDNISOLONE, PEMBROLIZUMAB, PREDNISOLONE | DrugsGivenReaction | CC BY-NC-ND | 33903584 | 19,423,555 | 2021-04-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dermatomyositis'. | A Rare Case of Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of Unknown Primary Origin.
BACKGROUND Pembrolizumab is a humanized monoclonal antibody against programmed cell death-1 protein. Pembrolizumab sometimes causes immune-related adverse events (irAEs). Dermatomyositis is a rare irAE of immune che... | LEVOFLOXACIN, METHYLPREDNISOLONE, PEMBROLIZUMAB, PREDNISOLONE | DrugsGivenReaction | CC BY-NC-ND | 33903584 | 19,423,555 | 2021-04-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | A Rare Case of Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of Unknown Primary Origin.
BACKGROUND Pembrolizumab is a humanized monoclonal antibody against programmed cell death-1 protein. Pembrolizumab sometimes causes immune-related adverse events (irAEs). Dermatomyositis is a rare irAE of immune che... | LEVOFLOXACIN, METHYLPREDNISOLONE, PEMBROLIZUMAB, PREDNISOLONE | DrugsGivenReaction | CC BY-NC-ND | 33903584 | 19,423,555 | 2021-04-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune-mediated enterocolitis'. | A Rare Case of Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of Unknown Primary Origin.
BACKGROUND Pembrolizumab is a humanized monoclonal antibody against programmed cell death-1 protein. Pembrolizumab sometimes causes immune-related adverse events (irAEs). Dermatomyositis is a rare irAE of immune che... | LEVOFLOXACIN, METHYLPREDNISOLONE, PEMBROLIZUMAB, PREDNISOLONE | DrugsGivenReaction | CC BY-NC-ND | 33903584 | 19,423,555 | 2021-04-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oral candidiasis'. | A Rare Case of Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of Unknown Primary Origin.
BACKGROUND Pembrolizumab is a humanized monoclonal antibody against programmed cell death-1 protein. Pembrolizumab sometimes causes immune-related adverse events (irAEs). Dermatomyositis is a rare irAE of immune che... | LEVOFLOXACIN, METHYLPREDNISOLONE, PEMBROLIZUMAB, PREDNISOLONE | DrugsGivenReaction | CC BY-NC-ND | 33903584 | 19,423,555 | 2021-04-27 |
What was the outcome of reaction 'Dermatomyositis'? | A Rare Case of Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of Unknown Primary Origin.
BACKGROUND Pembrolizumab is a humanized monoclonal antibody against programmed cell death-1 protein. Pembrolizumab sometimes causes immune-related adverse events (irAEs). Dermatomyositis is a rare irAE of immune che... | Recovering | ReactionOutcome | CC BY-NC-ND | 33903584 | 19,423,555 | 2021-04-27 |
What was the outcome of reaction 'Immune-mediated enterocolitis'? | A Rare Case of Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of Unknown Primary Origin.
BACKGROUND Pembrolizumab is a humanized monoclonal antibody against programmed cell death-1 protein. Pembrolizumab sometimes causes immune-related adverse events (irAEs). Dermatomyositis is a rare irAE of immune che... | Recovering | ReactionOutcome | CC BY-NC-ND | 33903584 | 19,423,555 | 2021-04-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Extrapyramidal disorder'. | Attenuation of COVID-19-induced cytokine storm in a young male patient with severe respiratory and neurological symptoms.
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), produces protean manifestations and causes indiscriminate havoc in mu... | BARICITINIB, CEFTRIAXONE, CHOLECALCIFEROL, DEXAMETHASONE, METOCLOPRAMIDE, REMDESIVIR, RISPERIDONE | DrugsGivenReaction | CC BY | 33905029 | 20,047,362 | 2021-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Attenuation of COVID-19-induced cytokine storm in a young male patient with severe respiratory and neurological symptoms.
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), produces protean manifestations and causes indiscriminate havoc in mu... | BARICITINIB, CEFTRIAXONE, CHOLECALCIFEROL, DEXAMETHASONE, METOCLOPRAMIDE, REMDESIVIR, RISPERIDONE | DrugsGivenReaction | CC BY | 33905029 | 20,047,362 | 2021-09 |
What was the administration route of drug 'BARICITINIB'? | Attenuation of COVID-19-induced cytokine storm in a young male patient with severe respiratory and neurological symptoms.
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), produces protean manifestations and causes indiscriminate havoc in mu... | Oral | DrugAdministrationRoute | CC BY | 33905029 | 20,047,362 | 2021-09 |
What was the administration route of drug 'REMDESIVIR'? | Attenuation of COVID-19-induced cytokine storm in a young male patient with severe respiratory and neurological symptoms.
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), produces protean manifestations and causes indiscriminate havoc in mu... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33905029 | 20,047,362 | 2021-09 |
What was the administration route of drug 'RISPERIDONE'? | Attenuation of COVID-19-induced cytokine storm in a young male patient with severe respiratory and neurological symptoms.
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), produces protean manifestations and causes indiscriminate havoc in mu... | Oral | DrugAdministrationRoute | CC BY | 33905029 | 20,047,362 | 2021-09 |
What was the dosage of drug 'METOCLOPRAMIDE'? | Attenuation of COVID-19-induced cytokine storm in a young male patient with severe respiratory and neurological symptoms.
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), produces protean manifestations and causes indiscriminate havoc in mu... | UNK (ONCE) | DrugDosageText | CC BY | 33905029 | 20,047,362 | 2021-09 |
What was the outcome of reaction 'Extrapyramidal disorder'? | Attenuation of COVID-19-induced cytokine storm in a young male patient with severe respiratory and neurological symptoms.
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), produces protean manifestations and causes indiscriminate havoc in mu... | Recovered | ReactionOutcome | CC BY | 33905029 | 20,047,362 | 2021-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug interaction'. | Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
BACKGROUND
In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. Howeve... | CYCLOPHOSPHAMIDE, DOXORUBICIN, GLECAPREVIR, PIBRENTASVIR, PREDNISOLONE, RITUXIMAB, VINCRISTINE SULFATE | DrugsGivenReaction | CC BY | 33906643 | 19,487,513 | 2021-04-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatitis C RNA increased'. | Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
BACKGROUND
In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. Howeve... | CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, PREDNISONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY | 33906643 | 19,476,370 | 2021-04-27 |
What was the dosage of drug 'DOXORUBICIN HYDROCHLORIDE'? | Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
BACKGROUND
In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. Howeve... | 50 MG/M2, CYCLIC, DAY 1 | DrugDosageText | CC BY | 33906643 | 19,476,370 | 2021-04-27 |
What was the dosage of drug 'DOXORUBICIN'? | Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
BACKGROUND
In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. Howeve... | DAY 1 | DrugDosageText | CC BY | 33906643 | 19,487,513 | 2021-04-27 |
What was the dosage of drug 'GLECAPREVIR'? | Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
BACKGROUND
In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. Howeve... | 300 MILLIGRAM DAILY; | DrugDosageText | CC BY | 33906643 | 19,487,513 | 2021-04-27 |
What was the dosage of drug 'PIBRENTASVIR'? | Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
BACKGROUND
In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. Howeve... | 120 MILLIGRAM DAILY; | DrugDosageText | CC BY | 33906643 | 19,487,513 | 2021-04-27 |
What was the dosage of drug 'PREDNISOLONE'? | Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
BACKGROUND
In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. Howeve... | 100 MILLIGRAM DAILY; DAY 1?5 | DrugDosageText | CC BY | 33906643 | 19,487,513 | 2021-04-27 |
What was the dosage of drug 'PREDNISONE'? | Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
BACKGROUND
In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. Howeve... | 100 MG, 1X/DAY, DAY 1?5 | DrugDosageText | CC BY | 33906643 | 19,476,370 | 2021-04-27 |
What was the dosage of drug 'VINCRISTINE SULFATE'? | Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
BACKGROUND
In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. Howeve... | DAY 1 | DrugDosageText | CC BY | 33906643 | 19,487,513 | 2021-04-27 |
What was the dosage of drug 'VINCRISTINE'? | Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
BACKGROUND
In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. Howeve... | 1.4 MG/M2, CYCLIC, DAY 1 | DrugDosageText | CC BY | 33906643 | 19,476,370 | 2021-04-27 |
What was the outcome of reaction 'Hepatitis C RNA increased'? | Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
BACKGROUND
In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. Howeve... | Recovered | ReactionOutcome | CC BY | 33906643 | 19,476,370 | 2021-04-27 |
What was the outcome of reaction 'Hepatitis C'? | Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
BACKGROUND
In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. Howeve... | Recovered | ReactionOutcome | CC BY | 33906643 | 19,476,370 | 2021-04-27 |
What was the outcome of reaction 'Hepatitis'? | Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
BACKGROUND
In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. Howeve... | Recovered | ReactionOutcome | CC BY | 33906643 | 19,476,370 | 2021-04-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Meningitis aseptic'. | Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
OBJECTIVE
To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS).
METHODS
This phase III, randomised, double-blind, placebo-controlled study enrolle... | CELECOXIB, OMEPRAZOLE, TOFACITINIB CITRATE | DrugsGivenReaction | CC BY-NC | 33906853 | 16,071,567 | 2021-04-27 |
What is the weight of the patient? | Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
OBJECTIVE
To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS).
METHODS
This phase III, randomised, double-blind, placebo-controlled study enrolle... | 70.3 kg. | Weight | CC BY-NC | 33906853 | 16,071,567 | 2021-04-27 |
What was the administration route of drug 'CELECOXIB'? | Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
OBJECTIVE
To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS).
METHODS
This phase III, randomised, double-blind, placebo-controlled study enrolle... | Oral | DrugAdministrationRoute | CC BY-NC | 33906853 | 16,071,567 | 2021-04-27 |
What was the administration route of drug 'OMEPRAZOLE'? | Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
OBJECTIVE
To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS).
METHODS
This phase III, randomised, double-blind, placebo-controlled study enrolle... | Oral | DrugAdministrationRoute | CC BY-NC | 33906853 | 16,071,567 | 2021-04-27 |
What was the administration route of drug 'TOFACITINIB CITRATE'? | Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
OBJECTIVE
To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS).
METHODS
This phase III, randomised, double-blind, placebo-controlled study enrolle... | Oral | DrugAdministrationRoute | CC BY-NC | 33906853 | 16,071,567 | 2021-04-27 |
What was the outcome of reaction 'Meningitis aseptic'? | Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
OBJECTIVE
To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS).
METHODS
This phase III, randomised, double-blind, placebo-controlled study enrolle... | Recovered | ReactionOutcome | CC BY-NC | 33906853 | 16,071,567 | 2021-04-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Drug induced oral erythema multiforme: Case report.
BACKGROUND
Drug induced oral erythema multiforme a rare clinical entity which involves only the lips and oral mucosa without skin involvement. These lesions are difficult in diagnosing with other oral ulcerative lesions with similar clinical manifestations.
This artic... | DICLOFENAC SODIUM | DrugsGivenReaction | CC BY | 33907086 | 19,259,260 | 2021-04-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dysphagia'. | Drug induced oral erythema multiforme: Case report.
BACKGROUND
Drug induced oral erythema multiforme a rare clinical entity which involves only the lips and oral mucosa without skin involvement. These lesions are difficult in diagnosing with other oral ulcerative lesions with similar clinical manifestations.
This artic... | DICLOFENAC SODIUM | DrugsGivenReaction | CC BY | 33907086 | 19,259,260 | 2021-04-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lip scab'. | Drug induced oral erythema multiforme: Case report.
BACKGROUND
Drug induced oral erythema multiforme a rare clinical entity which involves only the lips and oral mucosa without skin involvement. These lesions are difficult in diagnosing with other oral ulcerative lesions with similar clinical manifestations.
This artic... | DICLOFENAC SODIUM | DrugsGivenReaction | CC BY | 33907086 | 19,259,260 | 2021-04-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lip ulceration'. | Drug induced oral erythema multiforme: Case report.
BACKGROUND
Drug induced oral erythema multiforme a rare clinical entity which involves only the lips and oral mucosa without skin involvement. These lesions are difficult in diagnosing with other oral ulcerative lesions with similar clinical manifestations.
This artic... | DICLOFENAC SODIUM | DrugsGivenReaction | CC BY | 33907086 | 19,259,260 | 2021-04-30 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.